Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction

Onto better TRAILs for cancer treatment

(2016) D de Miguel et al.   CELL DEATH AND DIFFERENTIATION

CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1

(2015) Takuya Osada et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells

(2015) D. De Miguel et al.   Clinical & Translational Oncology

Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions

(2015) Avi Ashkenazi   JOURNAL OF CLINICAL INVESTIGATION

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

(2015) C Krupka et al.   LEUKEMIA

C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

(2015) Valerie R Wiersma et al.   mAbs

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display

(2015) Pradeep M. Nair et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

(2015) R. Stewart et al.   Cancer Immunology Research

PD-1 Restrains Radiotherapy-Induced Abscopal Effect

(2015) S. S. Park et al.   Cancer Immunology Research

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics

(2014) D. Massi et al.   ANNALS OF ONCOLOGY

TRAIL–Receptor Costimulation Inhibits Proximal TCR Signaling and Suppresses Human T Cell Activation and Proliferation

(2014) Corinna Lehnert et al.   JOURNAL OF IMMUNOLOGY

An optimized Protocol for Human M2 Macrophages using M-CSF and IL-4/IL-10/TGF-βYields a Dominant Immunosuppressive Phenotype

(2014) S. Mia et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity

(2013) Valerie R. Wiersma et al.   BRITISH JOURNAL OF HAEMATOLOGY

Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages

(2013) O. Bloch et al.   CLINICAL CANCER RESEARCH

Fn14•Trail Effectively Inhibits Hepatocellular Carcinoma Growth

(2013) Alexandra Aronin et al.   PLoS One

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Antibody-based fusion proteins to target death receptors in cancer

(2011) Marco de Bruyn et al.   CANCER LETTERS

Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells

(2011) M. de Bruyn et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

(2011) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

(2010) Jean-Charles Soria et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

(2010) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo

(2010) Marco de Bruyn et al.   Molecular Cancer

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family

(2009) E. Bremer et al.   CURRENT DRUG TARGETS

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy

(2009) Norma Lynn Fox et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1

(2009) Dong-Ming Kuang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL ONCOLOGY